World's Best Scientists 2026 revealed!

D-Index & Metrics

Discipline name D-Index World Ranking Current World Ranking National Ranking Current National Ranking Publications Citations
Immunology 78 1729 1576 850 763 239 27921

Mark J. Mulligan publications per year

The chart shows the history of publications by Mark J. Mulligan between 1988 and 2025, highlighting the no. of papers published in each year and offering an overview of the publication velocity of this scholar. Mark J. Mulligan published across 38 years, from 1988 to 2025, averaging 7.6 papers a year. Output peaked at 38 publications in 2021. 25 of the 289 publications appeared in the last two years.

No. of publications
10 20 30
Bar chart. Horizontal axis: year, 1988 to 2025. Vertical axis: number of publications, 0 to 38. Peak 38 publications in 2021. 1988: 1 publication 1989: 0 publications 1990: 2 publications 1991: 1 publication 1992: 2 publications 1993: 2 publications 1994: 2 publications 1995: 2 publications 1996: 3 publications 1997: 3 publications 1998: 5 publications 1999: 3 publications 2000: 3 publications 2001: 5 publications 2002: 4 publications 2003: 3 publications 2004: 2 publications 2005: 1 publication 2006: 1 publication 2007: 3 publications 2008: 4 publications 2009: 8 publications 2010: 2 publications 2011: 3 publications 2012: 7 publications 2013: 6 publications 2014: 11 publications 2015: 11 publications 2016: 7 publications 2017: 16 publications 2018: 12 publications 2019: 10 publications 2020: 25 publications 2021: 38 publications 2022: 27 publications 2023: 29 publications 2024: 14 publications 2025: 11 publications
1988 2025

289 publications in total across all disciplines

View publications per year as a table
Mark J. Mulligan: publications per year, 1988 to 2025
Year Publications
1988 1
1989 0
1990 2
1991 1
1992 2
1993 2
1994 2
1995 2
1996 3
1997 3
1998 5
1999 3
2000 3
2001 5
2002 4
2003 3
2004 2
2005 1
2006 1
2007 3
2008 4
2009 8
2010 2
2011 3
2012 7
2013 6
2014 11
2015 11
2016 7
2017 16
2018 12
2019 10
2020 25
2021 38
2022 27
2023 29
2024 14
2025 11
Total 289
Download as CSV

Mark J. Mulligan publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Mark J. Mulligan sits on this spectrum.

No. of scientists
50 100 150
Bar chart with 76 bars. Horizontal axis: publications, 62–71 to 807+. Vertical axis: number of scientists, 0 to 189. Most scientists, 189, have 152–161 publications. The last bar groups every scientist with 807 publications or more. The highlighted bar, 232–241 publications, is where this scientist sits. 62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 69 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientist 807+ publications: 100 scientists
62–71 publications 807+

This scientist: 239 publications — 48th percentile

48% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

View publications distribution as a table
Number of Immunology scientists by publication count, Research.com 2026 ranking edition. Based on 4,929 ranked scientists.
Publications Scientists This scientist
62–71 9
72–81 23
82–91 40
92–101 72
102–111 86
112–121 108
122–131 150
132–141 160
142–151 159
152–161 189
162–171 166
172–181 181
182–191 188
192–201 187
202–211 178
212–221 158
222–231 168
232–241 159 239
242–251 160
252–261 148
262–271 116
272–281 125
282–291 115
292–301 111
302–311 95
312–321 97
322–331 97
332–341 99
342–351 96
352–361 69
362–371 76
372–381 71
382–391 71
392–401 62
402–411 54
412–421 41
422–431 63
432–441 53
442–451 31
452–461 42
462–471 40
472–481 29
482–491 34
492–501 30
502–511 23
512–521 41
522–531 29
532–541 28
542–551 16
552–561 18
562–571 18
572–581 17
582–591 17
592–601 17
602–611 19
612–621 13
622–631 12
632–641 11
642–651 16
652–661 9
662–671 5
672–681 13
682–691 12
692–701 6
702–711 6
712–721 9
722–731 9
732–741 6
742–751 11
752–761 10
762–771 7
772–781 12
782–791 7
792–801 5
802–806 1
807+ 100
Download as CSV

Mark J. Mulligan D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Mark J. Mulligan sits on this spectrum.

No. of scientists
50 100 150 200
Bar chart with 60 bars. Horizontal axis: D-Index, 40–41 to 157+. Vertical axis: number of scientists, 0 to 201. Most scientists, 201, have 58–59 D-Index. The last bar groups every scientist with 157 D-Index or more. The highlighted bar, 78–79 D-Index, is where this scientist sits. 40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 163 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40–41 D-Index 157+

This scientist: 78 D-Index — 65th percentile

65% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

View D-Index distribution as a table
Number of Immunology scientists by D-index, Research.com 2026 ranking edition. Based on 4,929 ranked scientists.
D-Index Scientists This scientist
40–41 28
42–43 91
44–45 157
46–47 192
48–49 175
50–51 188
52–53 177
54–55 155
56–57 194
58–59 201
60–61 197
62–63 201
64–65 173
66–67 167
68–69 172
70–71 199
72–73 184
74–75 133
76–77 163
78–79 127 78
80–81 121
82–83 125
84–85 121
86–87 102
88–89 96
90–91 75
92–93 72
94–95 74
96–97 66
98–99 68
100–101 49
102–103 60
104–105 54
106–107 36
108–109 23
110–111 52
112–113 41
114–115 34
116–117 25
118–119 28
120–121 11
122–123 20
124–125 27
126–127 19
128–129 20
130–131 16
132–133 17
134–135 14
136–137 15
138–139 9
140–141 11
142–143 9
144–145 9
146–147 7
148–149 7
150–151 7
152–153 5
154–155 8
156 6
157+ 96
Download as CSV

Overview

Mark J. Mulligan is affiliated with New York University in the United States. Their research primarily focuses on Medicine, with a strong emphasis on Infectious Diseases, Immunology, and Epidemiology. This work also touches on related fields such as Molecular Biology and Animal Science and Zoology.

The scientist's research extensively covers topics connected to SARS-CoV-2 and COVID-19, including clinical research studies, detection and testing methods, vaccine coverage and hesitancy, as well as immunotherapy and immune responses. Additionally, their work includes investigations into animal virus infections and influenza virus research.

Recent notable publications by Mark J. Mulligan include:

  • Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults, 2020, Nature
  • Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates, 2020, New England Journal of Medicine
  • Homologous and Heterologous Covid-19 Booster Vaccinations, 2022, New England Journal of Medicine
  • The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates, 2021, Science Translational Medicine
  • Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials, 2021, Nature Communications

Mark J. Mulligan frequently collaborates with fellow researchers such as Marie I. Samanovic, Nadine Rouphael, Ramin S. Herati, Evan J. Anderson, and Lilin Lai.

The scientist's work has appeared in several publication venues, with multiple contributions to bioRxiv (Cold Spring Harbor Laboratory), Vaccines, Vaccine, Open Forum Infectious Diseases, and The Journal of Infectious Diseases.

Best Publications

  • Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates.

    Edward E. Walsh;Robert W. Frenck;Ann R. Falsey;Ann R. Falsey;Nicholas Kitchin

  • Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults.

    Mark J. Mulligan;Kirsten E. Lyke;Nicholas Kitchin;Judith Absalon

  • Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans

    Troy D Querec;Rama Akondy;Eva K Lee;Weiping Cao

  • Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection

    Jens Wrammert;Dimitrios G. Koutsonanos;Gui-Mei Li;Srilatha Edupuganti

  • Homologous and Heterologous Covid-19 Booster Vaccinations

    Unknown

  • Molecular signatures of antibody responses derived from a systems biology study of five human vaccines

    Shuzhao Li;Nadine Rouphael;Sai Duraisingham;Sandra Romero-Steiner

  • Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine

    Scott M. Hammer;Magdalena E. Sobieszczyk;Holly Janes;Shelly T. Karuna

  • Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines.

    Joseph D. Miller;Robbert G. van der Most;Rama S. Akondy;John T. Glidewell

  • Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus

    Lalita Priyamvada;Kendra M. Quicke;William H. Hudson;Nattawat Onlamoon

  • Origin and differentiation of human memory CD8 T cells after vaccination

    Rama Akondy;Mark Fitch;Srilatha Edupuganti;Shu Yang

  • The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): a randomised, partly blinded, placebo-controlled, phase 1 trial

    Nadine G Rouphael;Michele Paine;Regina Mosley;Sebastien Henry

  • Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells

    Gui-Mei Li;Christopher Chiu;Jens Wrammert;Megan McCausland

  • Magnitude of Functional CD8+ T-Cell Responses to the Gag Protein of Human Immunodeficiency Virus Type 1 Correlates Inversely with Viral Load in Plasma

    Bradley H. Edwards;Anju Bansal;Steffanie Sabbaj;Janna Bakari

  • The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates.

    Bryan E. Jones;Patricia L. Brown-Augsburger;Kizzmekia S. Corbett;Kathryn Westendorf

  • Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection

    Unknown

  • The Yellow Fever Virus Vaccine Induces a Broad and Polyfunctional Human Memory CD8+ T Cell Response

    Rama S. Akondy;Nathan D. Monson;Joseph D. Miller;Srilatha Edupuganti

  • Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine.

    Ann R Falsey;Magdalena E Sobieszczyk;Ian Hirsch;Stephanie Sproule

  • Systems Analysis of Immunity to Influenza Vaccination across Multiple Years and in Diverse Populations Reveals Shared Molecular Signatures

    Helder I. Nakaya;Thomas Hagan;Sai S. Duraisingham;Eva K. Lee

  • Protection against vaginal SIV transmission with microencapsulated vaccine

    Preston A. Marx;Richard W. Compans;Agegnehu Gettie;Jay K. Staas

  • Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials

    Martin R Gaudinski;Katherine V Houser;Kaitlyn M Morabito;Zonghui Hu

  • Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials.

    Cathrine Axfors;Cathrine Axfors;Andreas M. Schmitt;Andreas M. Schmitt;Perrine Janiaud;Janneke van’t Hooft;Janneke van’t Hooft

  • A Canarypox Vaccine Expressing Multiple Human Immunodeficiency Virus Type 1 Genes Given Alone or with Rgp120 Elicits Broad and Durable CD8+ Cytotoxic T Lymphocyte Responses in Seronegative Volunteers

    Thomas G. Evans;Michael C. Keefer;Kent J. Weinhold;Mark Wolff

Frequent Co-Authors

Nadine Rouphael
Nadine Rouphael Emory University
Rafi Ahmed
Rafi Ahmed Emory University
Paul A. Goepfert
Paul A. Goepfert University of Alabama at Birmingham
Evan J. Anderson
Evan J. Anderson Emory University
M. Juliana McElrath
M. Juliana McElrath University of Washington
Sharon E. Frey
Sharon E. Frey Saint Louis University
Bali Pulendran
Bali Pulendran Stanford University
Michael C. Keefer
Michael C. Keefer University of Rochester
Robert B. Belshe
Robert B. Belshe Saint Louis University
Wendy A. Keitel
Wendy A. Keitel Baylor College of Medicine

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, exploring related fields such as nursing can open diverse career opportunities. Many professionals consider advanced nursing roles specializing in mental health and psychiatric care, which often require strong clinical skills and advanced degrees.

One can pursue an easiest np program to start building foundational knowledge before moving into specialized areas like psychiatric mental health nurse practitioner roles. These programs balance accessibility with quality education, making them a popular choice for busy students.

When looking for specialized training, online options for online pmhnp programs with clinical placement are invaluable. They provide hands-on clinical experience, essential for certification and real-world practice, even in a virtual learning environment.

Cost is another critical factor; finding the cheapest psych np programs online can make advanced education more accessible without sacrificing quality. Scholarships and flexible payment plans often accompany these affordable programs.

Finally, understanding the financial outlook is important. According to recent data on doctorate in nursing salary, earning potential varies by location but generally reflects rewarding compensation for advanced practitioners.

Best Scientists Citing Mark J. Mulligan

Trending Scientists

Recently Published Articles